Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy
NCT02262832Phase 3Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2014
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of metreleptin in generalized lipodystrophy (GL), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Serum triglycerides and Serum hemoglobin A1C. Started Oct 2014; status: active, not recruiting.
02
Drugs
metreleptin
03
Conditions
generalized lipodystrophy (GL)
Beyond the preview
Go deeper on NCT02262832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262832.